Prospective, 6 Month, Open Label, Conversion Study From Mycophenolate Mofetil (MMF) to PRMYFORTIC*

Exclusion Criteria

• •GI symptoms assumed or known not to be caused by MPA therapy;
• •Acute rejection episode ≤ 4 weeks prior to study enrollment;
• •Liver disease interfering with enterohepatic recirculation, such as active hepatitis B, active hepatitis C, autoimmune hepatitis and liver cirrhosis;
• •Female patients who are pregnant, lactating or of child bearing potential and not practicing an approved method of birth control;
• •Active bacterial, viral or fungal infection;
• •Presence of psychiatric illness that in the view of the investigator would interfere with study requirements;
• •Known sensitivity to the study drug;
• •Receiving any investigational drug or have received any investigational drug within 30 days prior to study enrollment.